#VSTM

StockTitan

@stocktitan.net

1 week ago

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates Building on the insights from the China data, the tolerability profile that is emerging with VS-7375 in the U.S. has shown meaningful improvement and supports continued dose escalation,” said Dan Paterson, president and chief executive officer at Verastem Oncology.“ In 2026, our priorities are to continue driving a strong launch of AVMAPKI FAKZYNJA CO-PACK to...

#VSTM Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

2 months ago

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Verastem Oncology (Nasdaq: VSTM) will discontinue the RAMP 203 Phase 1/2 trial in advanced KRAS G12C NSCLC and stop further enrollment to reallocate resources to clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, and the RAMP 205 program. As of the November 26, 2025 data cutoff, 66 patients treated at the RP2D were evaluable. Key efficacy readouts: doublet, treatment-naïve ORR 40% (12/30) with mPFS 11.1 months; doublet, previously treated ORR 9.5% (2/21) with mPFS 3.7 months; triplet, treatment-naïve ORR 50% (2/4); VS-7375 showed a 69% response rate (11/16) in KRAS G12D NSCLC. No dose-limiting toxicities observed; most common TRAEs were nausea 56.8%, diarrhea 52.7%, and fatigue 45.9%.

#VSTM Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

2 months ago

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth Verastem Oncology (Nasdaq: VSTM) announced executive changes and clinical progress to accelerate growth. Michael Kauffman, M.D., Ph.D. moves from lead director to President of Development and joins the executive team; John Johnson is appointed Chairman of the Board. The company said COO Matthew Ros will depart as responsibilities are reallocated.Commercial launch activity for AVMAPKI FAKZYNJA CO-PACK has begun and the international Phase 3 confirmatory trial RAMP 301 completed an additional enrollment of 29 patients; topline primary-endpoint results are expected in mid-2027. The company remains blinded to the interim analysis results.

#VSTM Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

4 months ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced underwritten public offering of 8,543,794 shares of its common stock at an offering price to the public of $7.25 per share, and in lieu of common stock to certain...

#VSTM Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

4 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock Verastem Oncology (Nasdaq: VSTM) announced a proposed underwritten public offering of its common stock, with underwriters granted a 30-day option to buy up to an additional 15% of shares. The offering is subject to market conditions and may not be completed.Verastem said it will use net proceeds to fund commercial activities for the FDA-approved AVMAPKI FAKZYNJA co-pack for KRAS-mutated recurrent low-grade serous ovarian cancer, continue clinical R&D including the VS-7375 KRAS G12D program, and for working capital. A Form S-3 shelf was declared effective on Nov 20, 2023.

#VSTM Verastem Oncology Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

4 months ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates Verastem Oncology (Nasdaq: VSTM) reported Q3 2025 results and business updates on November 4, 2025. Key commercial and clinical highlights include $11.2M net product revenue in the first full quarter post-launch of AVMAPKI FAKZYNJA CO-PACK, completion of planned enrollment for the Phase 3 RAMP 301 trial (270 patients) with an IDMC-recommended one-time +29 patient increase, and VS-7375 clearing 400 mg and 600 mg monotherapy doses with no dose-limiting toxicities.Financials: total operating expenses $52.0M, GAAP net loss $98.5M (loss per share $1.35), non-GAAP adjusted net loss $39.4M, and cash, cash equivalents and investments of $137.7M, with runway into H2 2026 assuming product revenue and warrant exercises.

#VSTM Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

www.stocktitan.net/news/VSTM/verastem-oncol...

Sanzhi Kobzhan

@stocks2buy.net

4 months ago

Verastem, Inc. (NASDAQ:VSTM) Gains Momentum Among Investors

#VSTM 📈📉 www.stocks2buynow.com/newsitems/ve...

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Small-cap stocks registering bearish MACD crossover signal, Thu Sept 11th - #ENTO #VSTM #TCRX #SRCE #RBBN #PINC #OSBC #MGNX #LOVE #ICCM #HSON #FISI $ELVA $DAWN $COGT $CCRN $BCAX $ACIC $TEN $SCM $PINE $ONL $NMM $MFA - More: crystalequityresearch.com/trade-alerts... - #smallcap

InsiderFinance

@insiderfinance.com

7 months ago

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #XMTR 989.6x
2. #LOPE 342.0x
3. #VSTM 43.6x
4. #FTEK 42.8x
5. #BTG 23.3x

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

7 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#KDP, #TEM, #LX, #VSTM, #SG

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

7 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer Verastem Oncology (Nasdaq: VSTM) has received Fast Track Designation (FTD) from the FDA for VS-7375, its oral KRAS G12D inhibitor, for treating KRAS G12D-mutated pancreatic cancer in both first-line and previously treated settings.VS-7375 is currently being evaluated in a U.S. Phase 1/2a clinical trial, with plans for global expansion. The study began at a 400mg QD dose, based on efficacy data from GenFleet Therapeutics' China trial. The trial will assess the drug as monotherapy in pancreatic and non-small cell lung cancer, and in combination with cetuximab for advanced solid tumors, including colorectal cancer.Notably, the KRAS G12D mutation affects 37% of pancreatic cancers and is the most prevalent KRAS mutation in human cancers. Initial safety and efficacy results from GenFleet's Phase 1 study were presented at ASCO 2025.

#VSTM Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

8 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors Verastem Oncology (Nasdaq: VSTM) has announced the dosing of its first patient in a U.S. Phase 1/2a clinical trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, targeting advanced KRAS G12D mutant solid tumors.The trial, VS-7375-101, will begin with a monotherapy dose escalation phase starting at 400 mg, based on efficacious dosing from GenFleet Therapeutics' China study. The company plans to expand into monotherapy cohorts for pancreatic cancer and non-small cell lung cancer, while simultaneously evaluating VS-7375 in combination with cetuximab for colorectal cancer.This milestone follows Verastem's recent FDA approval, commercial launch, and positive results in first-line metastatic pancreatic cancer treatment.

#VSTM Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

www.stocktitan.net/news/VSTM/verastem-oncol...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks with declining money flow, Mon Jun 2nd - #REFI #PACK #ONIT #MSB #JILL #IIM #HLX #EVC #CLB #BHLB #AMRC #PDYN #OCFC #NCTY #KMTS #INM #HCSG #FBNC #CCCC #BCBP #AMWD #SLS #TIL #VSTM #ZTEK - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

9 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor Verastem Oncology reported promising updated data from GenFleet Therapeutics' Phase 1 study of GFH375 (VS-7375) in China, showing significant efficacy in treating KRAS G12D mutant cancers. The oral inhibitor demonstrated a 52% overall response rate (ORR) in pancreatic ductal adenocarcinoma patients and 42% ORR in non-small cell lung cancer patients. The study enrolled 62 patients, with 98% having metastatic disease. Safety data showed no dose-limiting toxicities across all dose levels, with mostly Grade 1/2 treatment-related adverse events. Based on these positive results, Verastem is advancing VS-7375's clinical program in the U.S. with a Phase 1/2a trial, starting at 400mg dosing. The company aims to evaluate the drug both as monotherapy and in combination treatments for various advanced solid tumors.

#VSTM Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

www.stocktitan.net/news/VSTM/verastem-oncol...

Shortfinder

@shortfinder.bsky.social

9 months ago

Verastem Plunges as Expected, SurgePays Loses Auditor Verastem tumbles after shareholder meeting, SurgePays feels heat of cash burn

Verastem Plunges as Expected, SurgePays Loses Auditor
open.substack.com/pub/shortfin...
#vstm #surg #short

Shortfinder

@shortfinder.bsky.social

9 months ago

Flush Coming for VSTM Financiers just got the green light to dump up to 10 million shares

Flush Coming for VSTM
open.substack.com/pub/shortfin...
#vstm #short

StockTitan

@stocktitan.net

9 months ago

Breakthrough: Tempus Partners on First-Ever FDA-Approved Test for KRAS-Mutant Ovarian Cancer Treatment New companion diagnostic test enables targeted therapy for rare ovarian cancer affecting young women. Partnership advances precision medicine in KRAS-mutant LGSOC. Learn more.

#TEM #VSTM Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

www.stocktitan.net/news/TEM/tempus-announce...

PRISM MarketView

@prismmarketview.bsky.social

10 months ago

Earnings Insights: Verastem Oncology Gears Up for a Transformational Year with FDA Approval and Expanding Pipeline Verastem Oncology is entering a pivotal phase in 2025 as it builds on clinical momentum, secures a major regulatory milestone, and strengthens its financial pos

#VSTM kicks off 2025 with FDA approval, a major KRAS G12D licensing deal, and a strong cash position. Next stop: ASCO data drops and global trial momentum.
#VerastemOncolog
prismmarketview.com/earnings-ins...

StockTitan

@stocktitan.net

10 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates Verastem Oncology (VSTM) reported Q1 2025 financial results and significant business updates. The company achieved a major milestone with the FDA approval of AVMAPKI™ FAKZYNJA™ CO-PACK on May 8, 2025, for treating adult patients with KRAS-mutated recurrent LGSOC. The company ended Q1 with $117.6 million in cash, strengthened to $192.6 million pro-forma after an April private placement. Key pipeline developments include: U.S. IND clearance for VS-7375 (oral KRAS G12D inhibitor) with Phase 1/2a study planned for mid-2025, completed enrollment in RAMP 205 trial's initial cohorts for pancreatic cancer, and continued RAMP 203 trial enrollment in lung cancer. Financial results showed a net loss of $52.1 million ($0.96 per share) for Q1 2025, with operating expenses of $44.2 million. The company plans to present updated clinical data at the upcoming 2025 ASCO Annual Meeting.

#VSTM Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

10 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer The FDA has granted accelerated approval to Verastem Oncology's (NASDAQ: VSTM) AVMAPKI™ FAKZYNJA™ CO-PACK, marking the first-ever treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy. The approval, based on the Phase 2 RAMP 201 study, came ahead of the June 30, 2025 PDUFA date. The trial demonstrated a 44% overall response rate in patients with KRAS mutant recurrent LGSOC, with duration of response ranging from 3.3 to 31.1 months. The oral combination therapy will be commercially available within one week. The approval is contingent upon verification of clinical benefit in a confirmatory trial. Verastem is launching Verastem Cares™ program to support patient access and reimbursement in the U.S.

#VSTM FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

www.stocktitan.net/news/VSTM/fda-approves-t...

StockTitan

@stocktitan.net

10 months ago

Verastem Lands $75M Backing from Elite Healthcare Investors to Launch Groundbreaking Cancer Treatment RTW Investments leads $75M private placement to accelerate ovarian cancer drug launch. Major healthcare funds join financing round. See development pipeline.

#VSTM Verastem Oncology Announces $75 million Private Placement

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

10 months ago

Revolutionary KRAS G12D Cancer Drug Gets FDA Green Light Following Promising Patient Responses New oral cancer drug shows early efficacy in pancreatic and lung cancers. Unique dual ON/OFF inhibition mechanism targets KRAS mutations. See trial results.

#VSTM Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

11 months ago

Revolutionary Cancer Drug Achieves Complete Response in Colorectal Cancer Study New data reveals superior potency of VS-7375 KRAS inhibitor, achieving complete tumor response in colorectal cancer models. Key findings at AACR 2025.

#VSTM Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

11 months ago

FDA Fast-Tracks Verastem's Cancer Drug as Company Reports $151M Cash Position Verastem secures FDA priority review for LGSOC treatment, reports $151.3M pro forma cash position. Key milestones include new IND filing and strategic partnerships for commercialization.

#VSTM Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

1 year ago

Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential New analyses from Phase 2 RAMP 201 trial support FDA Priority Review of avutometinib combination therapy for recurrent low-grade serous ovarian cancer

#VSTM Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

www.stocktitan.net/news/VSTM/verastem-oncol...

StockTitan

@stocktitan.net

1 year ago

Verastem Oncology Secures FDA Priority Review for Groundbreaking Cancer Drug Combination FDA grants priority review for avutometinib plus defactinib in KRAS mutant LGSOC treatment. PDUFA date set for June 2025 with planned commercial launch mid-year.

#VSTM Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

www.stocktitan.net/news/VSTM/verastem-oncol...